Allogene Therapeutics, Inc.
NASDAQ:ALLOBiotechnology
+$0.02 today
- Market cap
- $241.11M
- Beta
- 0.46
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$0.72
Volume 10.55M
Average 10.19M
ALLO Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Allogene Therapeutics, Inc.NASDAQ: ALLO
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $14.09M fell 6.0% year over year, ahead of the -11.2% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 2.3% from the prior quarter. Over 3 fiscal years it compounded at -10.5% a year.
Context
- Selling, general & admin increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 8 analysts of $3.95B (+6860.2%) for the fiscal year ending Dec 2026, a step up from the -12.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $14.09M+2.3% QoQ
- Last fiscal yearDec 2025
- $56.78M-12.9% YoY
- LTMMar 2026
- $55.88M-11.2% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 56.78M USD
- Year-over-year change
- -12.9%
- 4-year CAGR
- -6.4%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 56.78M | -12.9% |
| FY2024 | 2024-12-31 | 65.21M | -9.0% |
| FY2023 | 2023-12-31 | 71.67M | -9.6% |
| FY2022 | 2022-12-31 | 79.31M | +7.0% |
| FY2021 | 2021-12-31 | 74.11M | — |
Selling, General & Admin vs competitors
How ALLO compares with its peers on the latest reported figures
- ALLO's LTM Mar 2026 selling, general & admin of $55.88M is the 2nd highest of the 9 companies compared; the peer median is $33.37M.
- Its year-over-year change of -11.2% is the 4th highest of 9, against a peer median of -13.3%.
- Over three fiscal years its annual growth of -10.5% compares with a peer median of -8.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $142.24M | +17.3% | +60.5% | 153.6% | |
| LTM Mar 2026 | $55.88M | -11.2% | -10.5% | — | |
| LTM Dec 2025 | $51.27M | -12.6% | -8.1% | 193.1% | |
| LTM Mar 2026 | $42.34M | -49.3% | -18.0% | 670.4% | |
| LTM Mar 2026 | $36.25M | -1.5% | -0.1% | 323.5% | |
| LTM Mar 2026 | $30.49M | -13.9% | -7.9% | 67.6% | |
| LTM Mar 2026 | $22.18M | -32.4% | -9.0% | — | |
| LTM Mar 2026 | $17.8M | -55.8% | -27.2% | 76.9% | |
| LTM Mar 2026 | $9.18M | +20.3% | -1.1% | 13.5% | |
| Peer median (excluding ALLO) | $33.37M | -13.3% | -8.0% | 153.6% | |
Competitors are the stored peer set for ALLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 114.09M | 156K | 95K | 22K | 0 |
| Cost of Revenue | 0 | 14.3M | 0 | 0 | 12.36M |
| Gross Profit | 114.09M | (14.14M) | 95K | 22K | (12.36M) |
| Gross Margin | 100.0% | -9063.5% | 100.0% | 100.0% | — |
| Research & Development | 220.18M | 256.39M | 242.91M | 192.3M | 150.15M |
| Selling, General & Admin | 74.11M | 79.31M | 71.67M | 65.21M | 56.78M |
| Operating Expenses | 294.28M | 321.4M | 327.83M | 273.22M | 194.57M |
| Depreciation & Amortization | 10.45M | 14.3M | 14.2M | 13.64M | 12.36M |
| EBITDA | (171.6M) | (326.12M) | (313.07M) | (243.33M) | (177.45M) |
| EBITDA Margin | -150.4% | -209050.6% | -329543.2% | -1106031.8% | — |
| Operating Income | (180.19M) | (335.54M) | (327.74M) | (273.2M) | (206.93M) |
| Operating Margin | -157.9% | -215087.2% | -344986.3% | -1241813.6% | — |
| Interest Income | 1.71M | 4.57M | 18.31M | 20.15M | 19.29M |
| Interest Expense | 0 | 0 | 0 | 181K | 1.08M |
| Other Income / Expenses | (1.86M) | (4.88M) | 472K | 16.05M | 16.05M |
| Income Before Tax | (182.05M) | (340.41M) | (327.27M) | (257.15M) | (190.89M) |
| Pre-Tax Margin | -159.6% | -218214.1% | -344489.5% | -1168850.0% | — |
| Income Tax Expense | 0 | 0 | 0 | 443K | 0 |
| Net Income | (182.05M) | (340.41M) | (327.27M) | (257.59M) | (190.89M) |
| Net Margin | -159.6% | -218214.1% | -344489.5% | -1170863.6% | — |
| EPS (Basic) | (1.34) | (2.38) | (2.09) | (1.32) | (0.87) |
| EPS (Diluted) | (1.34) | (2.38) | (2.09) | (1.32) | (0.87) |
| Weighted Avg Shares | 135.82M | 143.15M | 156.93M | 194.81M | 220.62M |
| Weighted Avg Shares (Diluted) | 135.82M | 143.15M | 156.93M | 194.81M | 220.62M |
Allogene Therapeutics, Inc.
NASDAQ:ALLO
Intrinsic Alpha fair value
Locked
Current Price
$0.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.